Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:29:42 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:VCYT - VERACYTE INC - http://www.veracyte.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VCYT - Q0.118.50·37.312.419.45+0.251.31,359.625,8628,93919.11  19.54  19.0230.52  18.6116:12:00Apr 1615 min RT 2¢

Recent Trades - Last 10 of 8939
Time ETExPriceChangeVolume
16:12:00Q18.67-0.532
16:06:38Q19.450.25438,614
16:04:48Q19.450.25461
16:04:44Q19.450.25586
16:04:38Q19.450.2516
16:04:37Q19.450.25126
16:04:32Q19.450.2587
16:04:25Q19.450.253,563
16:04:23Q19.450.253,135
16:04:12Q19.450.251,314

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 08:30U:VCYTNews ReleaseVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
2024-02-27 17:55U:VCYTNews ReleaseVeracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
2024-02-22 16:05U:VCYTNews ReleaseVeracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
2024-02-21 17:00U:VCYTNews ReleaseVeracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
2024-02-08 08:00U:VCYTNews ReleaseVeracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
2024-02-06 08:15U:VCYTNews ReleaseVeracyte Completes Acquisition of C2i Genomics
2024-01-08 08:00U:VCYTNews ReleaseVeracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
2023-12-12 16:30U:VCYTNews ReleaseVeracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-01 16:05U:VCYTNews ReleaseReal-World Data Presented at SUO 2023 Show that Veracyte ¢ € ™s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
2023-11-29 08:30U:VCYTNews ReleaseClinical Validation Data Published in CHEST Demonstrate that Veracyte ¢ € ™s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
2023-11-22 08:30U:VCYTNews ReleaseVeracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
2023-11-07 16:05U:VCYTNews ReleaseVeracyte Announces Third Quarter 2023 Financial Results
2023-11-07 16:00U:VCYTNews ReleaseVeracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
2023-11-02 08:15U:VCYTNews ReleaseVeracyte to Participate in the Stephens Annual Investment Conference
2023-10-27 08:30U:VCYTNews ReleaseVeracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
2023-10-17 08:15U:VCYTNews ReleaseVeracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
2023-10-12 09:00U:VCYTNews ReleaseNew Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte ¢ € ™s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
2023-10-04 16:05U:VCYTNews ReleaseNew Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte ¢ € ™s Decipher Prostate Genomic Classifier
2023-09-28 16:05U:VCYTNews ReleaseNew Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte ¢ € ™s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
2023-09-28 08:15U:VCYTNews ReleaseVeracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023